# US 2025/0149142 A1 · Apparatus and method for determining a composition of a replacement therapy treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0149142 A1
- Document ID: US20250149142A1
- Status: Published application
- Kind: A1
- Application number: 18/950,152
- Filed: 2024-11-17
- Published: 2025-05-08
- Earliest claimed: 2021-06-22
- Inventors: David Haase
- Web page: https://patentgrep.com/patent/US20250149142A1

## CPC

- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G06N 3/088: Non-supervised learning, e.g. competitive learning
- G06N 3/09: Supervised learning
- G06N 5/022: Knowledge engineering; Knowledge acquisition
- G06N 20/00: Machine learning
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS

## Abstract

An apparatus and method for determining a composition of a replacement therapy treatment is presented, the apparatus at least a processor and a memory communicatively connected to the processor, the memory containing instructions configuring the at least a processor to receive a user input wherein the user input comprises at least an identifier and a constitutional history of the user, generate a first condition descriptor as a function of the user input, determine a composition of a replacement therapy treatment as a function of the first condition descriptor, wherein the determination comprises training a first machine-learning process using user training data, wherein the user training data correlates user inputs to compositions of the replacement therapy treatment and determining the composition as a function of the user input and the first machine learning process, and output the composition of the replacement therapy treatment as a function of the determination.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

An apparatus for determining a composition of a plasma exchange treatment, the apparatus comprising:
at least a processor; and
a memory communicatively connected to the at least a processor, the memory containing instructions configuring the at least a processor to:
receive an input from a remote sensor, wherein the input comprises a monitoring biomarker, wherein the monitoring biomarker is a biomarker that monitors the effects of a therapeutic agent at a user;
receive an identifier from the remote sensor, wherein the identifier links a user to a medical record;
generate a first condition descriptor as a function of the input, wherein the first condition descriptor is related to a change in the monitoring biomarker, wherein generating the first condition descriptor comprises utilizing a machine learning model and further comprises:
receiving reference biomarker training data;
training, iteratively, the machine learning model using the reference biomarker training data;
generate the first condition descriptor as a function of the input using the trained machine learning model;
incorporate new biomarkers as a function of new conditions into the biomarker training data;
iteratively regenerate the reference biomarker training data as a function of the first condition descriptor;
retrain the trained machine learning model as a function of the regenerated reference biomarker training data;
determine a plasma exchange treatment as a function of the change in the monitoring biomarker; and
output a description of a composition of the plasma exchange treatment as a function of the determination.

### Claim 22 (depends on 21)

The apparatus of claim 21, wherein the reference biomarker training data correlates a plurality of reference value data for each marker to a plurality of first condition data.

### Claim 23 (depends on 21)

The apparatus of claim 21, wherein training the machine learning model includes retraining the machine learning model with feedback from previous iterations of the machine learning model.

### Claim 24 (depends on 21)

The apparatus of claim 21, wherein the plasma exchange treatment comprises a series of treatments given over time.

### Claim 25 (depends on 21)

The apparatus of claim 21, wherein outputting the composition of the plasma exchange treatment comprises updating the user's identifier.

### Claim 26 (depends on 21)

The apparatus of claim 21, wherein the monitoring biomarker includes a measure of glycocalyx thickness, measured using sublingual video microscopy.

### Claim 27 (depends on 21)

The apparatus of claim 21, wherein the at least processor is further configured to determine an additional therapy to be administered in conjunction with the plasma exchange treatment.

### Claim 28 (depends on 27)

The apparatus of claim 27, wherein the additional therapy includes a dietary supplement configured to enhance an efficacy of the plasma exchange treatment.

### Claim 29 (depends on 21)

The apparatus of claim 21, further comprising a robot designed and configured to:
receive the description of the composition of the plasma exchange treatment; and
prepare the composition of the plasma exchange treatment for a user.

### Claim 30 (depends on 29)

The apparatus of claim 29, wherein the robot is configured to prepare a syringe that includes the composition of the plasma exchange treatment.

### Claim 31

A method for determining a composition of a plasma exchange treatment, the method comprises:
receiving, at a processor, an input from a remote sensor, wherein the input comprises a monitoring biomarker, wherein the monitoring biomarker is a biomarker that monitors the effects of a therapeutic agent at a user;
receiving, at the processor, an identifier from the remote sensor, wherein the identifier links a user to a medical record;
generating, at the processor, a first condition descriptor as a function of the input, wherein the first condition descriptor is related to a change in the monitoring biomarker, wherein generating the first condition descriptor comprises utilizing a machine learning model and further comprises:
receiving reference biomarker training data;
training, iteratively, the machine learning model using the reference biomarker training data;
generating, at the processor, the first condition descriptor as a function of the input using the trained machine learning model;
incorporating, at the processor, new biomarkers as a function of new conditions into the biomarker training data;
iteratively regenerating, at the processor, the reference biomarker training data as a function of the first condition descriptor;
retraining, at the processor, the trained machine learning model as a function of the regenerated reference biomarker training data;
determining, at the processor, a plasma exchange treatment as a function of the change in the monitoring biomarker; and
outputting, at the processor, a description of a composition of the plasma exchange treatment as a function of the determination.

### Claim 32 (depends on 31)

The method of claim 31, wherein the reference biomarker training data correlates a plurality of reference value data for each marker to a plurality of first condition data.

### Claim 33 (depends on 31)

The method of claim 31, wherein training the machine learning model includes retraining the machine learning model with feedback from previous iterations of the machine learning model.

### Claim 34 (depends on 31)

The method of claim 31, wherein the plasma exchange treatment comprises a series of treatments given over time.

### Claim 35 (depends on 31)

The method of claim 31, wherein outputting the composition of the plasma exchange treatment comprises updating the user's identifier.

### Claim 36 (depends on 31)

The method of claim 31, wherein the monitoring biomarker includes a measure of glycocalyx thickness, measured using sublingual video microscopy.

### Claim 37 (depends on 31)

The method of claim 31, further comprising determining, at the processor, an additional therapy to be administered in conjunction with the plasma exchange treatment.

### Claim 38 (depends on 37)

The method of claim 37, wherein the additional therapy includes a dietary supplement configured to enhance an efficacy of the plasma exchange treatment.

### Claim 39 (depends on 31)

The method of claim 31, further comprising implementing a robot designed and configured to:
receive the description of the composition of the plasma exchange treatment; and
prepare the composition of the plasma exchange treatment for a user.

### Claim 40 (depends on 39)

The method of claim 39, wherein the robot is configured to prepare a syringe that includes the composition of the plasma exchange treatment.
